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Abstract  Cervicouterine  cancer  screening  with  cytology  decreases  incidence  by  more  than
50%. The  cause  of  this  cancer  is  the  human  papilloma  virus  high  risk,  and  requires  a  sensitive  test
to provide  sufﬁcient  sensitivity  and  speciﬁcity  for  early  detection  and  greater  interval  period
when the  results  are  negative.  The  test  of  the  human  papilloma  virus  high  risk  is  effective  and
safe because  of  its  excellent  sensitivity,  negative  predictive  value  and  optimal  reproducibility,
especially  when  combined  with  liquid-based  cytology  or  biomarkers  with  viral  load,  with  higher
sensitivity  and  speciﬁcity,  by  reducing  false  positives  for  the  detection  of  cervical  intraepithelial
neoplasia  grade  2  or  greater  injury,  with  excellent  clinical  beneﬁts  to  cervical  cancer  screening
and related  infection  of  human  papilloma  virus  diseases,  and  is  currently  the  best  test  for  early
detection  infection  of  human  papillomavirus  and  the  risk  of  carcinogenesis.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Published  by  Masson  Doyma  México  S.A.  This
is an  open  access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
PALABRAS  CLAVE
Virus  del  papiloma
Detección  primaria  del  cáncer  cervicouterinohumano  de  alto
riesgo;
Métodos  de  detección
oportuna  de  cáncer
Resumen  La  detección  del  cáncer  cervicouterino  con  citología  disminuyó  su  incidencia  en  más
del 50%.  La  causa  de  este  cáncer  son  virus  del  papiloma  humano  de  alto  riesgo.  Se  requiere  de
una prueba  sensible  que  proporcione  la  sensibilidad  y  especiﬁcidad  suﬁcientes  para  su  detección
oportuna, y  mayor  periodo  de  intervalo  cuando  los  resultados  son  negativos.  La  prueba  del
virus del  papiloma  humano  de  alto  riesgo  es  eﬁcaz  y  segura  debido  a  su  excelente  sensibilidad,cervicouterino;
valour predictivo  negativo  y  reproducibilidad  óptima,  principalmente  cuando  se  combina  con Please cite this article as: Vargas-Hernández VM, Vargas-Aguilar VM, Tovar-Rodríguez JM. Detección primaria del cáncer cervicouterino.
ir Cir. 2015;83:448--453.
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Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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citología  en  base  líquida  o  biomarcadores  con  carga  viral,  con  mayor  sensibilidad  y  especiﬁci-
dad, reduciendo  los  falsos  positivos  para  la  detección  de  la  neoplasia  intraepitelial  cervical
grado 2  o  para  lesiones  mayores,  con  excelentes  beneﬁcios  clínicos  para  la  detección  del
cáncer cervicouterino  y  otras  enfermedades  relacionadas  con  la  infección  del  virus  del  papiloma
humano. Actualmente  es  la  mejor  prueba  para  la  detección  temprana  de  la  infección  por  virus
del papiloma  humano  y  el  riesgo  de  carcinogénesis.
© 2015  Academia  Mexicana  de  Cirugía  A.C.  Publicado  por  Masson  Doyma  México  S.A.  Este
es un  artículo  Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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negative  HPV-H,  in  either  the  rate  of  progression  or  regres-Background
Over  the  last  30  years,  the  mortality  rate  from  cervical  can-
cer  in  the  United  States  has  decreased  by  more  than  50%
as  a  result  of  screening  with  the  Papanicolaou  or  cytology
test,  which  is  being  offered  to  most  women  who  were  not
tested  in  the  past.  Cytology  has  been  developed  as  liquid
based  since  1928,  when  Dr.  Papanicolaou1--3 ﬁrst  reported
cancerous  cells  in  vaginal  smears,  and  published  his  results
in  1941.  Testing  for  human  papillomavirus  (HPV)  high  risk
(HPV-H)  was  approved  in  2000  and  the  ﬁrst  vaccine  against
HPV  came  onto  the  market  in  2006.  New  vaccines  are  cur-
rently  under  development  to  provide  broader  coverage  of
genotypes  and  greater  protection.4,5
Epidemiology
Cytology  has  lowered  the  incidence  and  rate  of  mortal-
ity  from  cervical  cancer  in  developed  countries  through
organised  screening  programmes.  Nevertheless,  more  than
68,000  and  12,000  new  cases  are  still  being  reported  each
year  in  Europe  and  the  United  States  respectively,  with  more
than  4000  deaths  from  cervical  cancer  in  the  United  States
in  2013.  However,  there  is  evidence  that  the  cervical  cancer
mortality  rate  had  decreased  even  before  the  HPV  vaccine
was  introduced:  the  overall  rate1,6 fell  from  10.2  to  8.5  cases
per  100,000  women  between  1998  and  2002.  In  Mexico,  9000
women  are  treated  annually  for  cervical  cancer  and  4000
die;  the  incidence  in  2008  was  19.2  and  mortality  was  9.7
per  100,000  women.  The  high  level  of  mortality  is  due  to
social  inequality.  The  National  Programme  for  the  Detection
of  Cervical  Cancer  was  started  in  Mexico  in  19747,8 and  a
slight  decrease  in  mortality  has  been  observed  since  1992,
which  has  fallen  from  13.3  in  2000  to  6--8  per  100,000  in
2008.
Screening  recommendations  change  as  technologies
develop.  The  sensitivity  of  a  single  Pap  test  in  detecting  a
cervical  intraepithelial  neoplasia  (CIN)  of  stage  2  or  higher
(CIN-2+)  or  high  grade  intraepithelial  squamous  lesions  is
low,2,7--11 and  for  it  to  be  implemented  demands  frequent
repetition  intervals,  a  high  level  of  organisation  and  high
costs.  Effective  biomarkers  are  needed  to  predict  the  risk  of
CIN.  The  most  important  of  these  are  those  which  genotype
HPV-H,  which  is  found  in  more  than  90%  of  CIN  and  cervical
cancers.12 The  clinical  course  of  the  new  HPV-H  screening
s
w
otrategies  is  reducing  the  cervical  cancer  mortality  rate,
s  there  are  more  than  40  different  genotypes  of  HPV-H
hich  cause  persistent  cervical  infections,  and  the  risk  of
rogression  of  CIN  differs  considerably  according  to  the  HPV-
 genotype.  But  the  majority  of  HPV-H  infections  are  rare
nd  most  HPV  tests  do  not  include  all  of  them.1 The  HPV-H
est  offers  high  sensitivity  in  detecting13--16 CIN-2+,  but  its
peciﬁcity  is  limited  because  most  HPV  infections  are  tran-
ient  and  only  a  low  proportion  of  HPV  infections  persist  and
rogress  to  become  intraepithelial  squamous  lesions.  Due  to
he  high  prevalence  of  HPV  infections  in  women  under  30,
PV-H  testing  is  not  currently  recommended  in  screening
omen  under  30.17
HPV-H  screening  in  women  with  abnormal  cytology  plays
 role  in  identifying  women  at  risk  of  residual  or  recur-
ent  disease  after  treatment  of  CIN.  Although  the  HPV-H
est  is  less  speciﬁc  than  cytology,  cytology  does  not  always
istinguish  between  transient  and  chronic  infection.4,14,18--21
he  expression  of  oncoproteins  E6  and  E7  of  the  HPV-
 genotypes,  in  squamous  epithelial  cells  of  the  cervix
auses  the  development  of  neoplastic  growth1 and  the  over-
xpression  of  the  biomarker  p16INK4a  (p16)22--27 which  is
ne  of  the  cyclin-dependent  kinase  inhibitors  which  pre-
ents  the  phosphorylation  of  the  retinoblastoma  protein
pRb)  and,  therefore,  plays  a  major  role  in  cell-cycle  reg-
lation.  Its  over-expression  is  frequently  observed  in  CIN
ssociated  with  HPV-H  infection  and  is  associated  with
ysfunction  of  the  retinoblastoma  protein  (pRb)  through
utations  which  occur  naturally.  It  can  also  be  associated
ith  oncoprotein  E7  of  HPV-16  which  causes  cell-cycle  alter-
tions,  over-expressing  p16.  This  biomarker  predicts  the
isk  of  progression  and  increases  the  higher  the  stage  of
IN:  CIN-1  (20.7%),  CIN-2  (80%)  and  CIN-3  (89.2%).  p16  over-
xpression  is  signiﬁcantly  greater  in  CIN  2  and  3  than  in  CIN-1
p  <  0.001).  This  biomarker  is  effective  compared  to  HPV-H
esting  in  patients  with  CIN-1  and  2.  In  patients  tested  for
PV-H,  80%  were  positive  and  the  HPV-H  infection  rate  also
ncreased  in  lesions  of  higher  stages,  in  CIN-1  (65.1%)  and
IN-2  and  3  (87.7%)  (p  <  0.001).28,29
However,  the  patients  who  were  infected  with  HPV-H
howed  a  greater  prevalence  of  progression  of  the  lesions,
ith  no  differences  between  the  groups  with  positive  andion  of  the  lesions  between  patients  infected  or  otherwise
ith  HPV-16  or  HPV-18  (p  =  0.60).7 Detecting  over-expression
f  p16  is  effective  in  managing  cytology  with  a  report  of
450  V.M.  Vargas-Hernández  et  al.
Table  1  Sensitivity,  speciﬁcity,  positive  and  negative  predictive  values  in  detecting  CIN-2+  and  CIN-3  in  women  aged  30--65.
Sensitivity  %  Speciﬁcity  %  PPV  %  NPV  %
Test  for  detecting  CIN-2+a
Pap  test  or  cytology  55.9  96.3  12.%  99.7
p16 84.7  96.2  15.3  99.9
HPV-H test** 93.3  96.2  96.2  99.9
Test for  CIN-3+a
Pap  test  or  cytology  59.0  96.1
p16 87.2  95.9
HPV-H test  96.2  92.7
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HPV-H: high risk human papillomavirus; NPV: negative predictive 
typical  squamous  cells  of  undetermined  signiﬁcance  (ASC-
S)  or  low-grade  intraepithelial  squamous  lesions20--25 and
or  women  testing  positive  for  HPV-H.  Sensitivity  for  CIN-
+  is  18%,  greater  than  cytology  (p  <  0.001)  in  women  of  all
ges,  with  95.2%  speciﬁcity  (Table  1).1,30 Speciﬁcity  of  cytol-
gy  with  p16  is  greater  with  the  HPV-H  test,  with  50%  fewer
alse  positives.  Dual-stain  cytology  and  the  combination  of
iomarkers  p16/Ki-67,  which  are  indicative  of  the  transfor-
ation  of  HPV  infection,  are  more  sensitive  and  speciﬁc  for
etecting  CIN-2+,  principally  in  women  under  30.  No  other
omplementary  test  is  currently  available,  and  alternatives
o  cytology  are  limited.6,17,19,28,29,31
CIN,  which  is  effectively  treated,  prevents  progression  to
ervical  cancer.  CIN-1  is  a  lesion  which  only  requires  moni-
oring  and  not  treatment:  10%  of  CIN-1  progress  to  CIN-3  or
ervical  cancer;  20%  of  CIN-2  progress  to  CIN-3  or  cervical
ancer  and  40%  of  CIN-2  remit  spontaneously.  Management
f  CIN-1  and  2  is  controversial:  some  remit  spontaneously.
hey  are  treated  with  destructive  or  excisional  procedures  in
atients  at  greater  risk  of  progression,  and  it  is  observed  that
hose  that  are  low  risk  remit  spontaneously,  but  it  is  difﬁcult
o  predict  the  outcome  for  each  individual  patient.31
rimary  detection  of  cervical  cancer
PV-H  tests,  for  detecting  and  preventing  lesions  that  are
recursors  of  cervical  cancer,  compared  with  cytology,  offer
0--70%  better  protection  against  this  cancer.  They  are
ffective  principally  in  women  aged  from  30  to  34,  and
hen  they  are  performed  every  5  years  offer  greater  pro-
ection  than  the  Pap  test  undertaken  every  3  years.32 The
ncorporation  of  the  HPV-H  test  in  developed  countries  in
creening  strategies  for  vaccinated  women  remains  to  be
etermined,  although  it  should  be  similar  to  that  of  women
ho  have  not  been  vaccinated.  In  the  short  term,  detection
ith  the  HPV-H  test  will  be  cheaper  and  offer  greater  secu-
ity  than  the  conventional  Pap  test.  Despite  these  beneﬁts,
ublic  health  programmes  will  have  logistical  problems  for
creening.  These  problems  include  determining  the  type  of
PV-H  test  to  be  used,  how  to  determine  the  age  and  appro-
riate  intervals  for  testing,  how  to  manage  HPV-H  positive
omen  and  ensure  the  quality,  adherence  and  application
f  HPV-H  testing  in  cervical  cancer  prevention  programmes.
he  HPV-H  test  is  more  effective  in  detecting  high-grade
ntraepithelial  squamous  lesions  and  in  the  prevention  of
d
a
ise.
; VPP: positive predictive value.
ervical  cancer  than  cytology  in  women  over  the  age  of  35,
nd  than  the  Pap  test  or  visual  examination  of  the  cervix  with
cetic  acid,  and  this  has  lowered  the  incidence  and  mortality
ate  of  cervical  cancer  in  developing  countries.2,14,33
ew  directives  for  the  detection  of  cervical  cancer
ew  directives  recommended  by  the  different  international
ssociations  for  the  early  detection  of  cervical  cancer2,15
ecommend  the  HPV-H  test  combined  with  the  Pap  test  in
omen  from  the  ages  of  30  to  65.  During  monitoring  after  a
egative  Pap  test,  it  has  been  demonstrated  that  screening
ntervals  of  5  years  with  HPV-H  testing  are  safer  than  inter-
als  of  3  years  using  the  Pap  test  alone.
With  these  recommendations,  the  proportion  of  cervical
denocarcinomas  has  reduced  by  40%  in  women  under  30;
y  35%  between  the  ages  of  30  and  34;  by  30%  between  35
nd  49,  and  by  23%  in  women  aged  over  50.  The  prevention
f  cervical  cancer  in  women  of  reproductive  age  is  a  prior-
ty,  and  therefore  detection  with  the  HPV-H  test  should  be
tarted  at  the  age  of  30.  These  directives  have  substantially
hanged  women’s  health  practices  and  cover  HPV  infection
nd  the  natural  history  of  cervical  cancer.2,15
Most  HPV  infections  are  transient,  the  body  is  capable  of
liminating  them  and  only  persistent  HPV  infections  result
n  cervical  cancer.  Most  women,  especially  under  the  age  of
1,  eliminate  the  infection  in  1--2  years.  Infections  in  women
ver  30  are  more  likely  to  persist,  and  the  rates  of  high-grade
esions  increase,  but  most  of  these  HPV-H  related  lesions
nly  progress  slowly  to  cervical  cancer.  On  average,  it  takes
.7  years  for  an  intraepithelial  squamous  lesion  to  progress
o  cervical  cancer.  The  new  directives  are1,2,15:
Screening  should  start  at  around  21  years  of  age,  regard-
ess  of  behaviour,  risk  factors  and  age  of  ﬁrst  sexual
elationship.
Women  aged  from  21  to  29  should  be  Pap  tested  every
 years,  without  HPV-H  testing.  Combined  testing  (Pap  and
PV-H  test)  should  take  place  from  the  age  of  30--65  every
 years.  HPV-H  is  the  preferred  recommendation,  but  cytol-
gy  alone  every  3  years  is  also  acceptable.  However  HPV-H
esting  alone  is  not  indicated.After  the  age  of  65,  future  detection  recommendations
epend  on  previous  screening.  If  the  results  have  been  neg-
tive,  these  women  do  not  require  routine  screening  and  it
s  not  necessary.  One  previous  negative  screening  means  3
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consecutive  negative  Pap  results  or  2  consecutive  negative
combined  test  results  over  the  past  5  years.  Screening  can-
not  stop  after  the  age  of  65  for  women  with  a  history  of
CIN-2,  CIN-3  and  should  continue.  Women  who  have  had  a
hysterectomy,  with  no  history  of  NIC-2  or  higher  stage,  are
no  longer  screened,  patients  with  CIN-2  or  CIN-3  prior  to  hys-
terectomy  continue  to  be  screened  with  the  Pap  test  every
3  years  for  20  years,  because  recurrent  cancer  can  develop
in  the  vaginal  vault  years  later.  There  is  no  clarity  on  HPV-
H  testing  in  this  scenario.  These  routine  guidelines  do  not
apply  to  women  who  are  under  immunosuppression,  are  HIV
positive,  who  have  been  exposed  to  diethylstilboestrol  in
utero,  or  who  have  a  history  of  cervical  cancer.2,7,8,15
Health  promotion
The  education  of  women  and  healthcare  professionals  is  an
essential  aspect  in  HPV-H  testing,  during  primary  screening,
and  the  clinical  and  psychological  management  of  women
with  normal  Pap  tests,  and  positive  HPV-H  tests  are  nec-
essary,  especially  if  women  under  30  are  included.  HPV
infection  is  a  matter  of  public  interest,  but  it  affects  people
emotionally  and  fear  of  cancer  increases  their  anxiety  and
this  has  an  impact  on  their  quality  of  life.34,35
The  best  time  to  give  information  on  HPV  infection
is  before  the  HPV-H  test  is  performed.  The  patient  is
more  attentive,  able  to  understand  and  their  anxiety  can
be  lessened.  Furthermore,  it  helps  with  further  follow-up
procedures  (for  example,  a  repeat  HPV-H  test,  cytology,
colposcopy  and  other  biological  markers)  in  relation  to  the
stratiﬁcation  of  risk.31 A  positive  HPV-H  test  does  not  repre-
sent  disease,  and  it  is  a  risk  factor.  If  the  HPV-H  test  is  still
positive  a  year  after  the  ﬁrst  test,  a  cytological  triage  or
non-invasive  tests  are  performed,  which  prevent  the  devel-
opment  of  cervical  cancer.  Current  algorithms  are  designed
for  women  who  are  aware  and  clinical  monitoring  is  easy
with  follow-up.  But  this  is  not  the  case  in  marginalised
communities  in  Latin  America,  Asia  and  Africa,  with  low
socio-economical  and  cultural  levels.  These  communities
are  those  which  are  most  affected  by  cervical  cancer,  where
prevalence  rates  of  this  cancer  are  higher  than  those  for
white  women  in  developed  countries.36
Discussion
Reports  over  the  past  2  decades  on  HPV-H  testing  have
deﬁnitively  demonstrated  the  association  between  the  HPV-
H  genotypes  and  cervical  cancer1 in  monitoring  treated
patients,  compared  with  the  conventional  Pap  test  or
colposcopy,  in  symptomatic  or  asymptomatic  women,  for
detecting  lesions  that  are  precursors  of  cervical  cancer,32
both  primary  cervical  screening  and  the  management  of
borderline  cytology  such  as  ASC-US.  HPV-H  tests  are  not
always  used  in  clinical  practice,  and  in  national  screening
programmes,  although  they  are  more  sensitive  than  the  Pap
test1,11--13 in  detecting  CIN-2+,  combined  HPV  and  Pap  testing
show  greater  negative  predictive  values  (NPV)14 for  CIN-2+.
Some  CIN-2  remit  spontaneously  and  the  greater  sensitivity
for  these  precancerous  lesions  and  cervical  cancer,  grouped
as  CIN-3+,  is  merely  over  diagnosis,  as  there  is  a  lower  future
incidence  of  CIN-3+.1,15
a
f
1
c451
Increased  sensitivity  has  2  major  clinical  outcomes:  a
educed  mortality  rate  and  extended  screening  interval,
ith  greater  detection,  lower  cost  and  higher  reproducibil-
ty.  The  HPV-H  test  is  more  sensitive  than  liquid-based
ytology  in  detecting  CIN-3  or  larger  lesions,  but  it  is
ess  speciﬁc  (92.0%  versus  53.3%;  a  difference  of  38.7%).
lthough  adding  liquid-based  cytology  to  the  HPV  test
ncreases  sensitivity  for  CIN-3  or  greater  lesions  (96.7%);  the
umber  of  positive  tests  has  also  increased  (35.2%).  How-
ver,  the  use  of  the  HPV-16  or  HPV-18  test  offers  better
nformation  with  similar  results.13,26,27
Screening  for  p16  in  positive  women  in  the  triage  study
or  ASC-US/LSIL  (ALTS)  designed  to  compare  3  manage-
ent  options,23 the  HPV-H  test  showed  greater  sensitivity
nd  identiﬁed  96.3%  (95%  CI:  91.6--98.8)  of  women  with
IN-3  or  greater  lesions,24 the  same  positive  predictive
alue  as  detection  with  conventional  cytology  (without
ncreasing  the  number  being  sent  for  colposcopy),  and  the
PV-H  test  maintained  higher  NPV.26 The  particular  value
f  the  HPV-H  test  is  greater  in  women  vaccinated  against
PV.  In  the  near  future  another  value  of  HPV-H  testing  is
xpected  due  to  vaccination  and  the  low  prevalence  of  HPV-
elated  disease.1,4,6,17--19,37--39. Residual  or  recurrent  disease
n  women  with  persistent  HPV-16  or  HPV-18  is  higher  (82%)
han  in  women  with  persistence  of  other  types  of  HPV-H  such
s  HPV  31,  33,  35,  45,  52,  and  58  (66.7%)  or  VPH  39,  51,  56,
9,  68,  26,  53,  66,  73,  y  82  (14.3%).  This  suggests  differ-
nt  levels  of  risk  for  the  progression  of  CIN.  Detecting  the
ersistence  of  certain  HPV-H  genotypes  has  the  potential
o  improve  the  management  of  these  patients.  Obviously,
ollow-up  after  treatment  must  include  conventional  cytol-
gy  and  HPV-H  testing  to  identify  patients  at  greater  risk  of
ecurrence  of  the  disease.1,38,39
In  the  past  50  years,  the  relative  proportion,  and  abso-
ute  incidence,  of  pre-invasive  and  invasive  glandular  lesions
f  the  cervix  have  been  increasing  in  western  countries.  In
950--1960  cervical  adenocarcinomas  represented  5%  of  cer-
ical  cancers;  in  1970  they  represented  from  20%  to  25%  of
ll  cervical  cancers,  the  majority  in  women  of  reproduc-
ive  age  who  required  fertility-conserving  surgery.  Although
he  management  of  in  situ  adenocarcinoma  is  controversial,
uring  follow-up  of  patients  with  in  situ  adenocarcinoma
ho  wanted  to  preserve  their  fertility,1 the  combination
f  the  HPV-H  test  and  the  Pap  test  demonstrated  greater
ensitivity  in  detecting  persistent  lesions,  with  100%  NPV
hich  is  useful  and  prevents  unnecessary  hysterectomies.
PV-H  tests  have  been  introduced  in  clinical  practice  as
urative  tests,  in  which  the  persistence  of  a  speciﬁc  geno-
ype  predicts  recurrence  short  term  and  the  absence  of
he  HPV  genotype,  associated  with  preoperative  diagnosis,
mply  successful  treatment  with  low  risk  of  recurrence.1,31,38
onclusion
PV  is  the  cause  for  the  development  of  cervical  cancer
nd  it  is  screened  using  the  HPV-H  test  versus  conventional
iquid-based  cytology;  sensitivity,  NPV  and  reproducibility;
nd  management  of  cytology  with  ASC-US  reporting  and
ollow-up  after  treatment  of  the  CIN.  HPV-H  tests  are  almost
00%  sensitive  and  NPV  to  identify  pre-neoplastic  lesions  or
ervical  cancer  is  the  main  test  in  primary  screening  for
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252  
hese  squamous  and  glandular  lesions  or  in  situ  adenomacar-
inoma;  moreover,  these  lesions  are  difﬁcult  to  detect.
enotyping  of  HPV-H  14  and  viral  load1,40 reduce  the  amount
f  false  positive  results,  respectively.  Sensitivity  to  CIN-3  or
reater  lesions  was  maintained  at  100%,  it  being  effective
nd  safe  in  detecting  cervical  cancer,  principally  in  combi-
ation  with  liquid-based  cytology  with  biomarkers  p16/Ki-67
hich  will  be  more  sensitive  and  speciﬁc,  in  detecting  CIN-
 or  greater  lesions,  and  better  clinical  performance  in
etecting  cervical  cancer  and  HPV  related  diseases.
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